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Abstract
This study investigated the release of prostaglandin E2 (PGE2)
from cartilage following an impact load in vitro and the possible
chondroprotective effect of cyclooxygenase-2 (COX-2)
inhibition using non-steroidal anti-inflammatory drugs (NSAIDs).
Explants of human articular cartilage were subjected to a single
impact load in a drop tower, and then cultured for 6 days in the
presence of either a selective COX-2 inhibitor (celecoxib; 0.01,
0.1, 1.0 and 10 μM) or a non-selective COX inhibitor
(indomethacin; 0.1 and 10 μM). The concentrations of PGE2
and glycosaminoglycans (GAGs), a measure of cartilage
breakdown, were measured in the explant culture medium at 3
and 6 days post-impact. Apoptotic cell death was measured in
frozen explant sections by the terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labelling (TUNEL) method.
PGE2 levels were increased by more than 20-fold in the medium
of explants at both 3 (p = 0.012) and 6 days (p = 0.004)
following impact, compared with unloaded controls. In the
presence of celecoxib and indomethacin, the PGE2 levels were
reduced in a dose-related manner. These inhibitors, however,
had no effect in reducing the impact-induced release of GAGs
from the cartilage matrix. Addition of celecoxib and
indomethacin significantly reduced the number of trauma-
induced apoptotic chondrocytes in cartilage explant sections.
In this study, a marked increase in PGE2 was measured in the
medium following an impact load on articular cartilage, which
was abolished by the selective COX-2 inhibitor, celecoxib, and
non-selective indomethacin. These inhibitors reduced
chondrocyte apoptosis but no change was observed in the
release of GAGs from the explants, suggesting that the COX/
PGE2 pathway is not directly responsible for cartilage
breakdown following traumatic injury. Our in vitro study
demonstrates that it is unlikely that COX-2 inhibition alone
would slow down or prevent the development of secondary
osteoarthritis.
Introduction
Articular cartilage is a highly specialised connective tissue that
covers the ends of long bones in diarthrodial joints. The tissue
protects the joint by distributing applied loads and providing a
low-friction, wear-resistant, lubricated surface to facilitate
movement. The cartilage matrix consists of collagen fibres that
reinforce a proteoglycan gel. The main protoeoglycan is aggre-
can, which comprises a protein core highly substituted with
polysulfated glycosaminoglycan (GAG) side chains.
Traumatic joint damage, such as may be sustained in a road
traffic accident or a sporting injury, is a known risk factor for
the subsequent development of secondary osteoarthritis (OA)
[1]. Injury can result in progressive cartilage loss causing pain,
swelling, inflammation and joint immobility. Ultimately, a joint
replacement may be required. However the processes result-
ing in cartilage breakdown following injury and the ability of the
tissue to repair itself are poorly understood. In humans, studies
have shown elevated levels of breakdown products from carti-
lage matrix many years after injury [2-4]. The relationship
between joint injury and OA development has also beenPage 1 of 10
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vitro [5,6].
Under normal physiological loading, articular cartilage is sub-
jected to a variety of stresses. These biomechanical factors
are believed to stimulate chondrocyte metabolism, providing a
mechanism for the cartilage to adapt to the demands imposed
by the body. However, in abnormal or injurious joint loading the
balance between cartilage matrix synthesis and degradation is
disturbed [7], resulting in tissue breakdown and the risk of pro-
gression of OA.
There is considerable evidence that the cytokine interleukin-1
(IL-1) plays an important role in OA, being up-regulated in OA
synovium and cartilage [8,9]. IL-1β expression in articular car-
tilage is also regulated by mechanical factors [10]. It induces
a catabolic cascade involving the cyclooxygenase (COX)
enzymes; two isoforms of which, COX-1 and COX-2, catalyse
the conversion of arachidonic acid to prostaglandins (PG), the
major pro-inflammatory product being prostaglandin E2
(PGE2) [11]. COX-1 is the constitutive form of the enzyme,
naturally expressed at low levels and essential to the normal
function of many tissues, whereas COX-2 is the inducible
form, which is commonly up-regulated following an insult to
the tissue [12]. Consequently, PGE2 has been found to be ele-
vated in cartilage, synovium and synovial fluid in OA joints
[13,14] and also in normal cartilage by prolonged static
mechanical loads [15]. Similarly COX-2, but not COX-1, has
been shown to be up-regulated in chondrocytes of OA carti-
lage [16]. This COX-2/PGE2 pathway is of major interest in
OA as the first line of treatment in this disease is the use of the
non-steroidal anti-inflammatory drugs (NSAIDs) for pain relief.
These drugs inhibit the activity of COX [17]. The non-selective
NSAIDs inhibit both COX-1 and COX-2 (e.g. indomethacin)
and more recently NSAIDs have been developed that are more
selective for COX-2 (e.g. celecoxib) exhibiting fewer
unwanted side effects.
Several studies, both in animal models [18] and in human
joints [19,20], have shown that apoptosis (programmed cell
death) is an important factor in the progression of OA. A pos-
itive correlation exists between severity of OA and percentage
of apoptotic cells [21]. Apoptosis occurs following mechani-
cal injury [22-26] and is thought to be initiated by IL-1β (in the
presence of tumour necrosis factor (TNF) α; [27]), which in
turn activates the caspase cascade [28]. As IL-1β is also
involved in activating the COX/PGE2 pathway and PGE2 is
reported to induce apoptosis in bovine articular chondrocytes
[29], the prostanoid may have a role in the increased apopto-
sis observed following trauma.
In an attempt to understand the physical and biochemical
changes occurring in articular cartilage following trauma, an in
vitro impact model has been developed [7,30]. This consists
of an instrumented drop tower, which enables an explant of
cartilage to be subjected to a controlled impact load [31].
The aim of this study was to ascertain whether PGE2 was
released by articular cartilage chondrocytes following an
impact load, and whether COX-2 inhibition using NSAIDs
could provide a chondroprotective role by preventing matrix
degradation. In addition, the role of COX inhibitors on trauma-
induced chondrocyte apoptosis was investigated.
Materials and methods
Cartilage explants
Human articular cartilage was obtained from femoral heads
retrieved during hemiarthroplasty for fractured neck of femur
within 12 h of surgery. Local Ethics Committee approval was
granted for this procedure. Full depth, circular explants (5 mm
diameter) of articular cartilage were removed from the under-
lying subchondral bone of human femoral heads (n = 3; ages
58, 63 and 68 years) using a cork borer and scalpel, and cul-
tured in Dulbecco's modified Eagle's medium (DMEM; Gibco,
Paisley, UK) supplemented with 10% foetal calf serum
(Globepharm, Guildford, UK), 100 IU/ml penicillin, 100 μg/ml
streptomycin, 0.25 μg/ml amphotericin B (Gibco) and 25 μg/
ml ascorbic acid (Sigma-Aldrich Co. Ltd., Gillingham, UK). To
minimise the effect of site variation and differing cartilage
thicknesses, test and control explants were taken from adja-
cent sites over the femoral head. In this study, cartilage was
removed from the underlying bone as the subchondral bone is
often too fragile and the surface too uneven for impact loading.
Following removal, and prior to impact loading, each explant
was placed in 2 ml of culture medium in a 24-well plate and
placed in an incubator at 37°C with 5% CO2. The explants
were allowed to equilibrate for 72 h as Fermor et al. showed
that there was an initial increase in PGE2 release from har-
vested cartilage explants, and that this stabilised after 72 h in
culture and remained stable for up to 7 days [32]. The wet
weight of each explant was measured prior to loading by plac-
ing in a sterile pre-weighed microcentrifuge tube containing
DMEM.
Impact loading
A specially designed drop tower was used to drop a mass on
to a cartilage explant from a known height [7,30,31]. The
explants were placed individually on the loading platen and
subjected to a single impact load using a 500 g mass dropped
from a height of 25 mm. The duration of each impact was
approximately 3 ms, with an energy of 0.13 J and a peak stress
of around 25 MPa. Impact loading conditions were chosen to
produce moderate, but not overly severe, damage to the tissue
based on our previous studies [7,30,33]. Control explants
were placed in the machine but not loaded. Following impact,
both control and loaded explants were re-cultured in fresh
medium (1 ml per explant) for 6 days in the presence of either
the selective COX-2 inhibitor celecoxib (donated by Pfizer Inc.,
New York, USA; 0.01, 0.1, 1.0 and 10 μM) or indomethacinPage 2 of 10
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both COX-1 and COX-2. The experiment was performed three
times, this being enough to obtain sufficient statistical power;
each femoral head yielded eight treatment groups, each con-
taining at least five explants (i.e. unloaded controls, loaded
without inhibitor, four loaded with different concentrations of
celecoxib and two loaded with different concentrations of
indomethacin added to the medium). Ethanol was used as the
solvent for the NSAIDs with a final concentration in the
medium of <0.01% v/v. Ethanol was added at the same con-
centration to the medium of the control explants. The ranges
of inhibitor concentrations in the culture medium were chosen
to include peak plasma levels of drug found in vivo. This was
1.8 μM for celecoxib following a single dose of 200 mg and
5.6–8.4 μM for indomethacin [34]. After 3 days the culture
medium was collected. Fresh medium, containing inhibitors as
before, was added to each culture well for a further 3 days.
The medium samples collected at days 3 and 6 were stored at
-20°C.
PGE2 release assay
PGE2 production was measured in the explant culture medium
using a commercially available enzyme-linked immunosorbent
assay (ELISA) kit (Prostaglandin E2 immunoassay, R&D Sys-
tems Ltd., Abingdon, UK). Results shown are measurements
of total PGE2 synthesis after 3 days and after 6 days (combin-
ing the two 3-day periods).
Glycosaminoglycan release assay
The concentration of GAGs, a measure of cartilage break-
down, was determined in the culture medium using the 1,9-
dimethylmethylene blue (DMMB) assay [35]. The method
used was modified from that described by Stone et al. [36] for
use in a 96-well plate. Standard curves were obtained using
concentrations of chondroitin 6-sulfate (Sigma) from 0–150
μg/ml at 10 μg/ml intervals. Duplicate aliquots (10 μl) of
explant culture medium and standards were mixed with 200 μl
of DMMB working solution in a 96-well plate, and the absorb-
ance read at 525 nm using a Dynatech MR5000 spectropho-
tometer (Dynex Technologies Ltd., Worthing, UK) plate reader
3 min after the addition of the dye. Biolinx software was used
to generate a standard curve and determine the concentration
of GAG in each medium sample. PGE2 and GAG concentra-
tions were normalised to the wet weight of each explant and
expressed per mg of cartilage.
Apoptosis detection
Articular cartilage explants were removed after 6 days in cul-
ture following impact load. They were snap frozen in OCT
embedding medium (Raymond A Lamb Ltd., Eastbourne, UK)
in isopentane cooled over liquid nitrogen. Four frozen (8 μm)
cartilage sections were cut from each explant, collected and
air dried onto SuperFrost Plus microscope slides (VWR Inter-
national, Lutterworth, UK). Apoptosis was evaluated by
TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labelling) staining using an ApoAlert DNA fragmenta-
tion assay kit (BD Biosciences Clontech, Palo Alto, CA, USA)
following the manufacturer's protocol. Following TUNEL stain-
ing, the sections were stained with propidium iodide (PI, 20
μg/ml; Sigma) for 8 min at room temperature to counterstain
the nuclei red. Positive control sections were treated with
DNase I (1 μg/ml; Roche Diagnostics Ltd., Lewes, UK) for 10
min before TUNEL staining and negative control sections were
treated with the nucleotide mix minus the TdT enzyme. Follow-
ing TUNEL staining, all sections were washed and covered
with Vectorshield fluorescent mounting medium (Vector Labo-
ratories Inc., Peterborough, UK). Images of each section were
taken, using the appropriate filters, with a digital camera (Cool-
SNAP, Roper Scientific GmbH, Germany.) attached to a fluo-
rescence microscope (Zeiss, Welwyn Garden City, UK). The
percentage of apoptotic cells was determined in each of the
four sections for each explant by first counting the green (flu-
orescein) apoptotic cells followed by the total cell count (PI,
red) with the aid of image analysis software (Image J, NIH,
Bethesda, MD, USA). In order to validate the TUNEL method,
some sections were stained with haematoxylin and eosin and
the percentage of apoptotic cells counted by observing the
morphology of the nucleus and cell membrane.
Statistical analysis
Differences in PGE2, GAG release and percentage apoptosis
between treatment groups were assessed using the unpaired
Student t test (two-tailed) using SPSS v.14 software (SPSS
Inc., Chicago, IL, USA). A p value less than 0.05 was consid-
ered significant. In Figures 1, 2, 3, 4, asterisks denote signifi-
cant differences; *p ≤ 0.05, **p ≤ 0.01. All data are expressed
as mean ± standard deviation (SD).
Results
PGE2 levels were increased 22-fold in the medium of explants
at 3 days (p = 0.012) following impact compared to unloaded
controls. By 6 days this increased further to 27-fold (p =
0.004) (Figure 1a). In the presence of celecoxib and indometh-
acin, the PGE2 levels were reduced in a dose-related manner
both at 3 days and, more significantly, 6 days (Figure 1b). At
the highest concentration (10 μM) the levels were reduced to
those of the unloaded controls by both inhibitors at both time-
points. The baseline concentrations in the medium of control
human cartilage explants were similar to those in other in vitro
studies [37-39].
The concentration of GAGs in the medium was significantly
higher in the loaded explants than in the unloaded controls at
both day 3 (p = 0.010) and day 6 (p = 0.003) following impact
(Figure 2a). However the addition of celecoxib or indometh-
acin to the culture medium had no effect on the release of
GAGs from the cartilage matrix at either 3 days or 6 days (Fig-
ure 2b). Therefore, in this study, COX inhibition following
impact load did not prevent proteoglycan depletion of
cartilage.Page 3 of 10
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compared with unloaded controls (p = 0.022). The apoptotic
chondrocytes were evenly distributed throughout the zones of
the loaded cartilage sections (Figure 3). Addition of the COX
inhibitors to the medium reduced the percentage of impact-
induced apoptosis at all doses and reached significance at 0.1
μM celecoxib (p = 0.034) and 10 μM indomethacin (p =
0.032) (Figure 4).
Discussion
A single impact load resulted in a marked increase in PGE2
release, the number of apoptotic cells, and the concentration
Figure 1
Release of PGE2 into culture medium following an impact load on articular cartilage explantsl i l il  l t . Explants of articular cartilage were impact loaded with 
a mass of 500 g dropped from 25 mm (0.13 J). The culture medium from each explant was collected at 3 days and 6 days following loading. The 
concentration of PGE2 in the medium was measured by ELISA, normalised to the wet weight of each explant and expressed per mg of cartilage. Day 
6 results represent the cumulative release of PGE2 (combining the two 3-day periods). Mean values (± standard deviation, n = 3) from three experi-
ments are shown. Each experiment used five replicates in each group. (a) Impact load significantly increased the concentration of PGE2 in the 
explant culture medium. Asterisks denote significant differences (*p ≤ 0.05, **p ≤ 0.01) between unloaded controls and impact loaded explants. (b) 
Celecoxib and indomethacin both reduced the release of PGE2 following an impact load. Asterisks denote significant differences (*p ≤ 0.05, **p ≤ 
0.01) between impact loaded explants with no inhibitor added and impact loaded explants with inhibitor.Page 4 of 10
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PGE2 lead directly to these other changes and hence provide
a target for early therapeutic intervention to delay or, even, pre-
vent later secondary OA?
Tissue damage resulted in an increase in PGE2 released to the
culture medium so that by day 3 after impact, the concentra-
tion was more than 20 times higher than in control groups. The
detailed course over time of this was not studied, but release
continued – albeit at a slower rate – over the next 3-day period.
This release could be inhibited in a dose-dependent fashion by
both celecoxib and indomethacin. Apoptosis was also
reduced but not in the same pattern. Indomethacin halved the
number of apoptotic cells at a concentration of 1 μM and
Figure 2
Release of glycosaminoglycans into the culture medium following an impact load on articular cartilage explantsl i  f ll i   i a t loa  on articular cartilage explants. Explants of human articular cartilage 
were impact loaded with a mass of 500 g dropped from 25 mm (0.13 J). The culture medium from each explant was collected at 3 days and 6 days 
following loading. The concentration of GAGs in the medium was measured with the DMMB assay, normalised to the wet weight of each explant and 
expressed per mg of cartilage. Day 6 results represent the cumulative release of GAGs (combining the two 3-day periods). Mean values (± standard 
deviation, n = 3) from three experiments are shown. Each experiment used five replicates in each group. (a) Impact load significantly increased the 
concentration of GAGs in the explant culture medium. Asterisks denote significant differences (**p ≤ 0.01) between unloaded controls and impact 
loaded explants. (b) The release of GAGs was unaffected by the addition of celecoxib or indomethacin.Page 5 of 10
(page number not for citation purposes)
Arthritis Research & Therapy    Vol 9 No 6    Jeffrey and Aspden halved it again at 10 μM. In contrast, celecoxib approximately
halved the number of apoptoptic cells but concentration
appeared to have little effect; maximal effect was found at 0.1
μM, but this was not significantly different from any of the other
concentrations used. Despite the reduction in apoptosis, nei-
ther inhibitor had any effect on matrix degradation, as indicted
by there being no change in GAG release.
The release of PGE2 by articular chondrocytes and its inhibi-
tion by indomethacin is well established [40]. Once released,
however, the effects of this prostanoid on the cartilage matrix
Figure 3
Determination of percentage of apoptotic cells in sections of articular cartilage using the TUNEL method. Cartilage explants were cultured for 2 
days, impact loaded and then cultured for a further 6 days before being frozen, sectioned (8 μm) and TUNEL stained. (a) Unloaded control showed 
very few TUNEL positive cells. (b) The percentage of apoptotic cells increased significantly following an impact load. (c) Addition of celecoxib (0.1 
μM) to the culture medium decreased the number of TUNEL positive cells in impact loaded explants. (d) The total cell count for each section was 
determined by counterstaining the nuclei red with propidium iodide. The bar represents 100 μm in all panels.Page 6 of 10
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on cartilage: increasing proteoglycan and collagen synthesis
[41], stimulating proliferation and aggrecan synthesis [42], up-
regulating glucocorticoid receptors [43] and, at low concen-
trations, stimulating collagen II synthesis. All these effects are
possibly mediated by insulin-like growth factor 1 (IGF-1) via an
autocrine loop [44]. However, this response was reported to
be biphasic in chondrocytes in vitro because at higher con-
centrations of PGE2 collagen synthesis was reduced precipi-
tously [44]. In earlier studies we showed that a static load of 1
MPa on human articular cartilage explants in vitro resulted in
an increased expression of IL-1β [45] and PGE2 [15], though
cyclic loading produced no measurable change in either IL-1β
or PGE2 suggesting that this is a pathological response. In this
study, we show that physical injury to cartilage following
impact results in a significant increase in PGE2.
The increase in the percentage of apoptotic cells was similar
to that we measured previously with human cartilage using the
same drop-tower model [46]. The role of PGE2 in promoting
apoptosis, however, remains unclear. Addition of exogenous
PGE2 to bovine articular chondrocytes in vitro has been
shown to cause apoptosis through a cAMP-dependent
pathway [29]. However in human chondrocytes from OA car-
tilage, Notoya et al. [47] found that PGE2 had no effect on
chondrocyte apoptosis itself, but the prostanoid enhanced
apoptosis induced by exogenous nitric oxide and this effect
could be prevented by COX-2 inhibition. In contrast, PGE2 has
been reported to protect chondrocytes from apoptosis
induced by actinomycin-D [48]. In addition, PGE2 is a
chondrocyte growth inhibitor that requires NO for its produc-
tion [49], and both PGE2 and NO are downstream mediators
of IL-1. The partial, dose-independent reduction we found sug-
gests that a cofactor role for PGE2 is possibly more likely than
a direct effect. Further studies are required to investigate the
role of NO and IL-1β.
Hashimoto et al. [21] linked chondrocyte apoptosis to matrix
destruction. In this study however, the inhibition of apoptosis
by the addition of celecoxib or indomethacin was not found to
reduce the amount of GAGs, the breakdown products of car-
tilage proteoglycans, lost from loaded explants. This result is
similar to that we previously found, culturing human articular
cartilage explants with a broad spectrum caspase inhibitor (Z-
VAD-FMK) reduced the percentage of impact-induced
apoptotic chondrocytes but was unable to reduce the amount
of GAGs released into the medium following impact [50].
Since articular cartilage is not vascularised and does not con-
Figure 4
Celecoxib and indomethacin reduced the percentage of impact-induced apoptotic chondrocytes following an impact load. Following loading (as 
described in Figure 3) and culture in the presence of celecoxib and indomethacin for 6 days, the percentage of apoptotic cells in frozen sections (8 
μm) of articular cartilage explants was measured using the TUNEL assay. Mean values (± standard deviation, n = 12). Asterisks denote significant 
differences between the groups as shown. (*p ≤ 0.05).Page 7 of 10
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nism for removal of apoptotic bodies following chondrocyte
apoptosis. It has been shown that these apoptotic bodies
express properties that contribute to pathologic matrix
destruction [27]. Therefore, although matrix degradation, as
measured by GAG release, was unchanged in this study, COX
inhibition may still have chondroprotective effects by reducing
the percentage of impact-induced apoptotic cells remaining in
the tissue (and, therefore, there would be fewer potentially
destructive apoptotic bodies). Together, though, these studies
indicate that apoptosis alone is not driving matrix breakdown
and that, once started, degradative enzymic activity may not be
under direct cellular control. This may be because these
enzymes are sequestered extracellularly in inactive forms and
activation leads to a positive feedback pathway that is then out
of direct control of the cells. Alternatively, enzymic activation is
controlled by a different signalling pathway, though this then
raises the question as to why the remaining cells cannot rec-
ognise this activity and inhibit it? The cells have been shown
to be able to increase their levels of matrix biosynthesis follow-
ing impact-induced damage [7] so perhaps matrix breakdown
is part of a repair response to try to remove damaged tissue
and replace it. Assuming, however, that it is important clinically
to reduce matrix degradation, a two-pronged approach to
treating damaged tissue would then be required; one agent to
rescue the cells from apoptosis and another to inhibit enzymic
degradation. The complexity of these mechanisms requires
further investigation, in particular addition of exogenous PGE2
and subsequent measurement of proteoglycan synthesis in
this system would demonstrate any anabolic effects. However,
we have shown that inhibiting PGE2 in impact-damaged carti-
lage at least partially prevented the increase in apoptotic cells
otherwise found after 6 days.
Both celecoxib and indomethacin could abolish the increase in
PGE2. Celecoxib is 375 times more selective for COX-2 than
COX-1 [51] whereas indomethacin is generally considered to
be non-selective. Several studies have shown that COX inhib-
itors have an effect on cartilage metabolism. COX-2 inhibition
has no direct effect on normal, healthy cartilage, but in the
presence of IL-1β or TNFα it restores proteoglycan turnover
[52]. Additionally, Hajjaji et al. [53] found that celecoxib had a
favourable effect on the metabolism of proteoglycans and
hyaluronic acid in samples of OA cartilage in vitro. Non-selec-
tive NSAIDs have differing effects on cartilage metabolism.
Some stimulate, some have no effect, and others – including
indomethacin – inhibit matrix synthesis [54,55]. Mastbergen et
al. [38] have shown that in OA cartilage, NSAIDs with low
COX-2/COX-1 selectivity exhibit adverse effects whereas
high COX-2/COX-1 selective NSAIDs either had no effect or
had reparative properties. Since in our study the non-selective
NSAID indomethacin inhibited impact-induced apoptosis,
future experiments with an experimental selective COX-1
inhibitor (i.e. SC-560) may be of use to investigate the precise
role of COX-1 in this impact model. In patients, selective COX-
2 inhibition would appear to confer beneficial effects on artic-
ular cartilage metabolism while avoiding the harmful effects of
COX-1 inhibition, such as gastric irritation and inhibition of
matrix synthesis, though possible cardiovascular effects of
COX-2 inhibition have yet to be resolved.
Conclusion
This study has shown that an impact load on articular cartilage
results in a marked increase in PGE2 synthesis. This increase
could be abolished by both the selective COX-2 inhibitor,
celecoxib, and by non-selective indomethacin. Chondrocyte
apoptosis, induced by impact, was also reduced by COX-2
inhibition. No change was observed in the release of GAGs
from the explants in the presence of these inhibitors, however,
suggesting that the COX/PGE2 pathway is not directly
responsible for cartilage breakdown following traumatic injury.
The inhibition by COX inhibitors of PGE2 release following
trauma may provide an opportunity for early clinical interven-
tion to reduce cell death from apoptosis. Our in vitro study
suggests that it is unlikely, however, that COX-2 inhibition
alone would slow down or prevent the development of sec-
ondary osteoarthritis.
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